Fahmida Khatoon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fahmida Khatoon has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Fauzia Ashfaq
Clinical Nutrition Department, Applied Medical Sciences College, Jazan University, Jazan, Saudi Arabia
3 shared publications - Mohammad Idreesh Khan
Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia
3 shared publications - Jwaher Haji Alhaji
Department of Health Sciences, College of Applied Studies, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
2 shared publications - Abdulrahman Ahmed Alsayegh
Department of Clinical Nutrition, College of Nursing and Health Sciences, Jazan University, Jazan, Saudi Arabia
1 shared publication - Abeer M. Aljaadi
Department of Clinical Nutrition, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 21955, Saudi Arabia
1 shared publication - Afnan S. Salaka
Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 21955, Saudi Arabia
1 shared publication
Latest Publications
- 7 October 2024
- Published by SAGE Publications in Rejuvenation Research
- Vol. 27 (5) , 145-153
Role of NQO1 Gene Involvement and Susceptibility of T2DM Among Saudi Arabia Population
NQO1 disruption enhances susceptibility to oxidative stress during hyperglycemia and is a significant contributor to the development and progression of diabetes. Oxidative stress has been linked to several symptoms, including hyperglycemia, reactive oxygen species buildup, high blood pressure, and the expression of inflammatory markers. Therefore, the present research aimed to evaluate the genetic abnormality of NQO1 (rs1800566, C609T) gene polymorphism, expression, and vitamin-D level assessment among Type 2 diabetes mellitus (T2DM) patients. The study included 100 newly diagnosed T2DM cases and 100 healthy individuals as healthy controls. Total RNA was extracted from the whole blood using the TRIzol method, and further cDNA was synthesized, and expression was evaluated. There is a significant difference in NQO1 (rs1800566, C609T) genotype distribution among the T2DM patients and healthy controls ( p = 0.04). Compared with the NQO1 CC wild-type genotype, the NQO1 CT heterozygous genotype had an odds ratio of 1.96 (1.08–3.55), and the NQO1 TT mutant type genotype had an odds ratio of 3.31 (0.61–17.77). Significantly decreased expression of NQO1 mRNA was observed with heterozygous CT ( p < 0.0001) and homozygous mutant TT genotype ( p = 0.0004), compared with homozygous wild-type CC genotype. NQO1 mRNA expression level was also compared with vitamin D levels among the T2DM patients. T2DM patients with vitamin D deficiency had 1.83-fold NQO1 mRNA expression, while vitamin D insufficient and sufficient T2DM cases had 3.31-fold ( p < 0.0001) and 3.70-fold ( p < 0.0001) NQO1 mRNA expression. It was concluded that NQO1 (rs1800566, C609T) CT and TT genotypes played a significant role in the worseness of type II diabetes mellitus, and decreased expression of NQO1 mRNA expression could be an essential factor for disease worseness as well as hypermethylation could be a factor for reduced expression leading to disease severity. The decreased NQO1 mRNA expression with heterozygous CT and mutant TT genotype associated with vitamin D deficiency may contribute to disease progression.
- 7 October 2024
- Published by SAGE Publications in Rejuvenation Research
- Vol. 27 (5) , 145-153
Role of NQO1 Gene Involvement and Susceptibility of T2DM Among Saudi Arabia Population
NQO1 disruption enhances susceptibility to oxidative stress during hyperglycemia and is a significant contributor to the development and progression of diabetes. Oxidative stress has been linked to several symptoms, including hyperglycemia, reactive oxygen species buildup, high blood pressure, and the expression of inflammatory markers. Therefore, the present research aimed to evaluate the genetic abnormality of NQO1 (rs1800566, C609T) gene polymorphism, expression, and vitamin-D level assessment among Type 2 diabetes mellitus (T2DM) patients. The study included 100 newly diagnosed T2DM cases and 100 healthy individuals as healthy controls. Total RNA was extracted from the whole blood using the TRIzol method, and further cDNA was synthesized, and expression was evaluated. There is a significant difference in NQO1 (rs1800566, C609T) genotype distribution among the T2DM patients and healthy controls ( p = 0.04). Compared with the NQO1 CC wild-type genotype, the NQO1 CT heterozygous genotype had an odds ratio of 1.96 (1.08–3.55), and the NQO1 TT mutant type genotype had an odds ratio of 3.31 (0.61–17.77). Significantly decreased expression of NQO1 mRNA was observed with heterozygous CT ( p < 0.0001) and homozygous mutant TT genotype ( p = 0.0004), compared with homozygous wild-type CC genotype. NQO1 mRNA expression level was also compared with vitamin D levels among the T2DM patients. T2DM patients with vitamin D deficiency had 1.83-fold NQO1 mRNA expression, while vitamin D insufficient and sufficient T2DM cases had 3.31-fold ( p < 0.0001) and 3.70-fold ( p < 0.0001) NQO1 mRNA expression. It was concluded that NQO1 (rs1800566, C609T) CT and TT genotypes played a significant role in the worseness of type II diabetes mellitus, and decreased expression of NQO1 mRNA expression could be an essential factor for disease worseness as well as hypermethylation could be a factor for reduced expression leading to disease severity. The decreased NQO1 mRNA expression with heterozygous CT and mutant TT genotype associated with vitamin D deficiency may contribute to disease progression.
- 17 June 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 398, 111114
Withaferin A alleviates inflammation in animal models of arthritis by inhibiting the NF-κB pathway and cytokine release
- 17 June 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 398, 111114
Withaferin A alleviates inflammation in animal models of arthritis by inhibiting the NF-κB pathway and cytokine release
- Open Access
Atherogenic sdLDL-cholesterol and resistin association with vitamin B12 in relation to Body Mass Index
Introduction Obesity is a known risk factor for many chronic diseases and is a growing global health concern and poor health outcomes have consistently been linked to body mass index (BMI). Small dense low-density lipoprotein (sdLDL) changes brought on by obesity may increase the likelihood of endothelium penetration and subsequent atherogenesis. Numerous tissues’ metabolic and secretory functions are altered by obesity, which may also increase the serum resistin level. Methods Present study included 300 participants with diffent BMI among them sdLDL and resistin was evaluated. HbA1c was analysed by whole blood of EDTA and the serum were thawed sample was used for lipid parameters (TG, cholesterol, HDL, LDL, VLDL and sdLDL) and vitamin B12 analysis as well as resistin level was analysed by ELISA. Results Study observed higher HbA1c (%, p=0.0004), LDL (mg/dl) (Conclusion Study concluded that the obese participants had higher TG, cholesterol, VLDL, LDL and lower HDL level. The most importantly, higher sdLDL level and resistin level was observed in obese participants as well as higher sdLDL and resistin could influence the higher lipid parameters (TG, cholesterol, VLDL, LDL) and lower HDL level. It was also observed that obese participants had lower vitamin B12 level and could lead to other metabolic error.
Open AccessAtherogenic sdLDL-cholesterol and resistin association with vitamin B12 in relation to Body Mass Index
Introduction Obesity is a known risk factor for many chronic diseases and is a growing global health concern and poor health outcomes have consistently been linked to body mass index (BMI). Small dense low-density lipoprotein (sdLDL) changes brought on by obesity may increase the likelihood of endothelium penetration and subsequent atherogenesis. Numerous tissues’ metabolic and secretory functions are altered by obesity, which may also increase the serum resistin level. Methods Present study included 300 participants with diffent BMI among them sdLDL and resistin was evaluated. HbA1c was analysed by whole blood of EDTA and the serum were thawed sample was used for lipid parameters (TG, cholesterol, HDL, LDL, VLDL and sdLDL) and vitamin B12 analysis as well as resistin level was analysed by ELISA. Results Study observed higher HbA1c (%, p=0.0004), LDL (mg/dl) (Conclusion Study concluded that the obese participants had higher TG, cholesterol, VLDL, LDL and lower HDL level. The most importantly, higher sdLDL level and resistin level was observed in obese participants as well as higher sdLDL and resistin could influence the higher lipid parameters (TG, cholesterol, VLDL, LDL) and lower HDL level. It was also observed that obese participants had lower vitamin B12 level and could lead to other metabolic error.
- Open Access
Comparison of TCN-2 (776C>G) Gene Polymorphism and Vitamin B12 Status with Different Body Mass Index among Saudi Adults
Background: Overweight and obesity (OO) are significant public health issues, and many elements, including genetics, epigenetics, sedentary lifestyle, comorbid conditions, psychological and environmental pressures, have been linked to OO. More than 2 billion people are presently impacted by the global obesity epidemic, which is still advancing relentlessly. It is a significant public health concern and a major contributor to healthcare costs, because it increases the chance of developing conditions such as heart disease, stroke, type 2 diabetes, and chronic kidney disease (CKD). Using the ranges of 18.5–25 for normality, 25–30 for overweight, and 30 for obesity, BMI (in kg/m2) is used to identify obesity. Vitamin deficiency is one of the causative factors associated with the increasing trend of obesity. Altered vitamin B12 status is a multifactorial trait; changes in B12 status are produced by several single nucleotide polymorphisms (SNPs) in various genes that interact with the environment. They also support coordinated efforts to alter the built environment that is causing the obesity pandemic. Therefore, the present study aimed to evaluate the TCN-2 (776C>G) gene alteration and vitamin B12 levels with respect to different body mass index, as well as associating BMI with other biochemical parameters. Methods: 250 individuals were involved in the study; among them, 100 were in the healthy weight range category (BMI: 18.5 to 2), 100 were overweight (BMI: 25.0 to 30 kg/m2). Participants visited during the screening program were subjected to blood pressure measurement, and further peripheral blood samples were drawn from all the participants in plain as well as in EDTA vials for biochemical (lipid profile and vitamin B12 level) analysis and single nucleotide polymorphism studies. Extracted DNA from whole blood collected in EDTA vials using kit protocol was used for genotyping by PCR-RFLP. Results: The levels of systolic (p < 0.0001) and diastolic blood pressures (p < 0.0001), HDL (p < 0.0001), LDL (p = 0.04), TG (p < 0.0001), cholesterol (p < 0.0001), and VLDL (p < 0.0001) showed significant differences between healthy controls, overweight, and obese groups. The healthy control TCN-2 (776C>G) genotypes were compared with those of overweight and obese participants, and compared to the healthy controls it was observed that overweight (p = 0.01) and obese (p = 0.002) subjects had significant differences in TCN-2 (776C>G) genotypes. For genotypes CG and GG, the odds ratio was 1.61 (0.87–2.95; p = 0.12), and 3.81 (1.47–9.88; p = 0.005) for overweight participants, respectively, and obese participants’ calculated odds ratios were 2.49 (1.16–5.36; p = 0.01) and 5.79 (1.93–17.35; p = 0.001), respectively. The relative risk for genotypes CG and GG, was 1.25 (0.93–1.68; p = 0.12), 2.17 (1.12–4.17; p = 0.02) for overweight participants, while the obese participants’ calculated relative risks were 1.31 (1.03–1.68; p = 0.01) and 2.02 (1.12–3.65; p = 0.001), respectively. Vitamin B12 levels were analyzed, and it was observed that a significant difference existed among overweight (305.5 pmol/L, p < 0.0001) and obese patients (229 pmol/L, p < 0.0001), respectively, as compared to healthy controls (385.5 pmol/L). Correlation analysis showed a significant association of vitamin B12 level with TG, cholesterol and VLDL; it showed a negative correlation, suggesting that decreases in B12 levels may impact the lipid profile. Conclusion: The study concluded that a predisposition to the GG genotype of TCN-2 gene polymorphism (776C>G) may increase susceptibility to obesity and the related complications, and higher odds and relative risk for the GG genotype may increase the risk of having obesity and further related complications. Lower vitamin B12 levels were linked with obesity and overweight, and impaired lipid parameters suggested that lower vitamin B12 may impact the altered lipid profile.
Open AccessComparison of TCN-2 (776C>G) Gene Polymorphism and Vitamin B12 Status with Different Body Mass Index among Saudi Adults
Background: Overweight and obesity (OO) are significant public health issues, and many elements, including genetics, epigenetics, sedentary lifestyle, comorbid conditions, psychological and environmental pressures, have been linked to OO. More than 2 billion people are presently impacted by the global obesity epidemic, which is still advancing relentlessly. It is a significant public health concern and a major contributor to healthcare costs, because it increases the chance of developing conditions such as heart disease, stroke, type 2 diabetes, and chronic kidney disease (CKD). Using the ranges of 18.5–25 for normality, 25–30 for overweight, and 30 for obesity, BMI (in kg/m2) is used to identify obesity. Vitamin deficiency is one of the causative factors associated with the increasing trend of obesity. Altered vitamin B12 status is a multifactorial trait; changes in B12 status are produced by several single nucleotide polymorphisms (SNPs) in various genes that interact with the environment. They also support coordinated efforts to alter the built environment that is causing the obesity pandemic. Therefore, the present study aimed to evaluate the TCN-2 (776C>G) gene alteration and vitamin B12 levels with respect to different body mass index, as well as associating BMI with other biochemical parameters. Methods: 250 individuals were involved in the study; among them, 100 were in the healthy weight range category (BMI: 18.5 to 2), 100 were overweight (BMI: 25.0 to 30 kg/m2). Participants visited during the screening program were subjected to blood pressure measurement, and further peripheral blood samples were drawn from all the participants in plain as well as in EDTA vials for biochemical (lipid profile and vitamin B12 level) analysis and single nucleotide polymorphism studies. Extracted DNA from whole blood collected in EDTA vials using kit protocol was used for genotyping by PCR-RFLP. Results: The levels of systolic (p < 0.0001) and diastolic blood pressures (p < 0.0001), HDL (p < 0.0001), LDL (p = 0.04), TG (p < 0.0001), cholesterol (p < 0.0001), and VLDL (p < 0.0001) showed significant differences between healthy controls, overweight, and obese groups. The healthy control TCN-2 (776C>G) genotypes were compared with those of overweight and obese participants, and compared to the healthy controls it was observed that overweight (p = 0.01) and obese (p = 0.002) subjects had significant differences in TCN-2 (776C>G) genotypes. For genotypes CG and GG, the odds ratio was 1.61 (0.87–2.95; p = 0.12), and 3.81 (1.47–9.88; p = 0.005) for overweight participants, respectively, and obese participants’ calculated odds ratios were 2.49 (1.16–5.36; p = 0.01) and 5.79 (1.93–17.35; p = 0.001), respectively. The relative risk for genotypes CG and GG, was 1.25 (0.93–1.68; p = 0.12), 2.17 (1.12–4.17; p = 0.02) for overweight participants, while the obese participants’ calculated relative risks were 1.31 (1.03–1.68; p = 0.01) and 2.02 (1.12–3.65; p = 0.001), respectively. Vitamin B12 levels were analyzed, and it was observed that a significant difference existed among overweight (305.5 pmol/L, p < 0.0001) and obese patients (229 pmol/L, p < 0.0001), respectively, as compared to healthy controls (385.5 pmol/L). Correlation analysis showed a significant association of vitamin B12 level with TG, cholesterol and VLDL; it showed a negative correlation, suggesting that decreases in B12 levels may impact the lipid profile. Conclusion: The study concluded that a predisposition to the GG genotype of TCN-2 gene polymorphism (776C>G) may increase susceptibility to obesity and the related complications, and higher odds and relative risk for the GG genotype may increase the risk of having obesity and further related complications. Lower vitamin B12 levels were linked with obesity and overweight, and impaired lipid parameters suggested that lower vitamin B12 may impact the altered lipid profile.
- Open Access
MD Simulation Studies for Selective Phytochemicals as Potential Inhibitors against Major Biological Targets of Diabetic Nephropathy
Diabetes is emerging as an epidemic and is becoming a public health concern worldwide. Diabetic nephropathy is one of the serious complications of diabetes, and about 40% of individuals with diabetes develop diabetic nephropathy. The consistent feature of diabetes and its associated nephropathy is hyperglycemia, and in some cases, hyperamylinemia. Currently, the treatment includes the use of medication for blood pressure control, sugar control, and cholesterol control, and in the later stage requires dialysis and kidney transplantation, making the management of this complication very difficult. Bioactive compounds, herbal medicines, and extracts are extensively used in the treatment and prevention of several diseases, and some are reported to be efficacious in diabetes too. Therefore, in this study, we tried to identify the therapeutic potential of phytochemicals used in in silico docking and molecular dynamic simulation studies using a library of 5284 phytochemicals against the two potential targets of type 2 diabetes-associated nephropathy. We identified two phytochemicals (i.e., gentisic acid and michelalbine) that target human amylin peptide and dipeptidyl peptidase-4, respectively, with good binding affinity. These phytochemicals can be further evaluated using in vitro and in vivo studies for their anti-hyperglycemia and anti-hyperamylinemia effects.
Open AccessMD Simulation Studies for Selective Phytochemicals as Potential Inhibitors against Major Biological Targets of Diabetic Nephropathy
Diabetes is emerging as an epidemic and is becoming a public health concern worldwide. Diabetic nephropathy is one of the serious complications of diabetes, and about 40% of individuals with diabetes develop diabetic nephropathy. The consistent feature of diabetes and its associated nephropathy is hyperglycemia, and in some cases, hyperamylinemia. Currently, the treatment includes the use of medication for blood pressure control, sugar control, and cholesterol control, and in the later stage requires dialysis and kidney transplantation, making the management of this complication very difficult. Bioactive compounds, herbal medicines, and extracts are extensively used in the treatment and prevention of several diseases, and some are reported to be efficacious in diabetes too. Therefore, in this study, we tried to identify the therapeutic potential of phytochemicals used in in silico docking and molecular dynamic simulation studies using a library of 5284 phytochemicals against the two potential targets of type 2 diabetes-associated nephropathy. We identified two phytochemicals (i.e., gentisic acid and michelalbine) that target human amylin peptide and dipeptidyl peptidase-4, respectively, with good binding affinity. These phytochemicals can be further evaluated using in vitro and in vivo studies for their anti-hyperglycemia and anti-hyperamylinemia effects.
- Open Access
- 31 March 2020
- Published by Gomal Medical College Dera Ismail Khan in Gomal Journal of Medical Sciences
- Vol. 18 (01) , 39-42
SURFACTANT PROTEIN D LEVELS WITH OBESITY AND TYPE 2 DIABETES MELLITUS
Surfactant protein D (SP-D) is an important component of pulmonary innate immunity. It is mainly produced by type 2 alveolar and bronchial epithelial cells, but is also found in extra pulmonary tissues and blood. It acts as a primary host defense against inhaled microorganisms. It also enhances adaptive immunity by activating T cells. SP-D deficiency can lead to upper and lower respiratory tract infections. Obesity has reached global epidemic proportions in both adults and children and is associated with numerous co-morbidities and insulin resistance. Type 2 diabetes & obesity are highly associated with recurrent pulmonary & extra pulmonary infections. The primary objective of this study was to determine the association of serum surfactant protein D levels with obesity and type 2 diabetes mellitus.
- 31 March 2020
- Published by Gomal Medical College Dera Ismail Khan in Gomal Journal of Medical Sciences
- Vol. 18 (01) , 39-42
Open AccessSURFACTANT PROTEIN D LEVELS WITH OBESITY AND TYPE 2 DIABETES MELLITUS
Surfactant protein D (SP-D) is an important component of pulmonary innate immunity. It is mainly produced by type 2 alveolar and bronchial epithelial cells, but is also found in extra pulmonary tissues and blood. It acts as a primary host defense against inhaled microorganisms. It also enhances adaptive immunity by activating T cells. SP-D deficiency can lead to upper and lower respiratory tract infections. Obesity has reached global epidemic proportions in both adults and children and is associated with numerous co-morbidities and insulin resistance. Type 2 diabetes & obesity are highly associated with recurrent pulmonary & extra pulmonary infections. The primary objective of this study was to determine the association of serum surfactant protein D levels with obesity and type 2 diabetes mellitus.